A microneedle drug delivery system for GLP-1 class drugs and its control method

The microneedle drug delivery system, which integrates a glucose detection module, a drug delivery module, and a drug detection module, can monitor and precisely control GLP-1 release in real time. This solves the problem of inaccurate determination of the drug release endpoint in existing technologies, and enables minimally invasive and personalized GLP-1 drug delivery, improving the accuracy and safety of treatment.

CN123059263APending Publication Date: 2026-11-10NINGBO JUNKANG MEDICAL TECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611441563.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-17
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing microneedle drug delivery systems cannot monitor GLP-1 release concentration in situ, leading to inaccurate determination of drug release endpoints and the risk of insufficient or excessive drug administration, making it difficult to achieve individualized and precise treatment.

Method used

A microneedle drug delivery system was designed, comprising a glucose detection module, a drug loading module, and a drug detection module. The system monitors the glucose concentration and GLP-1 drug release concentration in subcutaneous tissue fluid in real time through a closed-loop control system, achieving closed-loop control throughout the entire process. The system employs a combination of a glucose oxidase and peroxidase dual-enzyme system, a polypyrrole drug loading matrix and an electronically controlled release unit, and a gold nanoparticle layer and a GLP-1 specific antibody to achieve precise drug release.

Benefits of technology

It enables minimally invasive and painless administration of GLP-1 drugs, precisely controls the drug release process, avoids drug overdose or underdose, improves the accuracy and safety of individualized treatment, and is suitable for people with metabolic diseases who require long-term medication management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059263A_ABST
    Figure CN123059263A_ABST
Patent Text Reader

Abstract

This invention discloses a microneedle drug delivery system for GLP-1 drugs and its control method. The microneedle drug delivery system includes: a microneedle carrier module comprising multiple arrayed conductive microneedles; a glucose detection module for real-time monitoring of glucose concentration in subcutaneous tissue fluid; a drug loading module for loading and controlling the release of GLP-1 drugs; and a drug detection module for real-time monitoring of the release concentration and cumulative release amount of the GLP-1 drugs. The glucose detection module, the drug loading module, and the drug detection module are respectively integrated on their corresponding conductive microneedles. A closed-loop control system is connected to the glucose detection module, the drug loading module, and the drug detection module, respectively, for receiving glucose detection signals and drug detection signals, and controlling the drug release process of the drug loading module according to the signals. This invention achieves a closed-loop control of the entire process of "detection-release-monitoring-termination," effectively avoiding insufficient or excessive drug administration, and significantly improving the accuracy and safety of drug delivery.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of medical device technology, and in particular to a GLP-1 class drug microneedle delivery system and its control method. Background Technology

[0002] Obesity and type 2 diabetes, among other metabolic diseases, have become global public health problems and are closely related to cardiovascular disease, hypertension, and many other conditions. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as benaglutide, exert their weight-loss and blood sugar-lowering effects through multiple mechanisms, including suppressing appetite, delaying gastric emptying, increasing satiety, and promoting energy expenditure. They have become an important class of drugs for the treatment of metabolic diseases. However, the current clinical administration of GLP-1 drugs is still mainly subcutaneous injection, which has the following limitations: fixed dosage, making it difficult to dynamically adjust according to the patient's real-time blood glucose levels and metabolic status; frequent injections bring pain and infection risks, resulting in low long-term patient adherence; and the inability to know the drug concentration and cumulative release in the body in real time poses a safety risk of underdosing or overdosing.

[0003] Microneedle transdermal drug delivery technology can penetrate the stratum corneum of the skin without stimulating pain nerves in the dermis, achieving minimally invasive and painless drug delivery, providing a new approach for the delivery of GLP-1 drugs. In existing technologies, patent document CN120860452A discloses a PEBA-based smart insulin microneedle patch that utilizes the glucose-responsive release of insulin via PBA-diol bonds, with a flexible substrate liquid metal circuit monitoring blood glucose in real time and providing feedback to adjust the voltage. However, its design is primarily focused on insulin, and the closed-loop control relies solely on blood glucose concentration as a feedback signal, lacking monitoring of drug release concentration. Furthermore, the release mechanism is mainly based on passive chemical response, making it difficult to actively and accurately control the drug release process. Another patent document, CN122250998A, discloses a microneedle sensor and a smart microneedle closed-loop system, employing a carbon aerogel glucose sensor and polypyrrole / sulfobutyl-β-cyclodextrin for electrically controlled release of metformin, achieving linkage between blood glucose monitoring and on-demand drug delivery. However, the drug it carries is cationic small-molecule metformin, which relies on electrostatic adsorption by anionic dopant for drug delivery. GLP-1 drugs, such as benaglutide, are anionic large-molecule peptides with fundamentally different molecular weights, charge properties, and spatial conformations compared to metformin, making it impossible to simply use this drug delivery system. Furthermore, this closed-loop system also relies solely on blood glucose concentration as a feedback signal, lacking in-situ monitoring of drug release concentration, making it impossible to determine whether the preset therapeutic dose has been reached and to precisely terminate drug release.

[0004] In summary, existing closed-loop microneedle drug delivery systems generally rely solely on blood glucose concentration as a feedback signal, lacking in-situ real-time monitoring of the release concentration and cumulative release amount of GLP-1 drugs. This makes it impossible to achieve closed-loop control of the entire process of detection, release, monitoring, and termination, leading to inaccurate determination of the drug release endpoint and the risk of insufficient or excessive drug administration. Consequently, these systems fail to meet the needs of individualized and precise treatment with GLP-1 drugs. Summary of the Invention

[0005] To address the shortcomings of existing technologies, the technical problem to be solved by this invention is: how to monitor the release concentration of GLP-1 in situ and thereby accurately control drug release in a closed loop.

[0006] To address the aforementioned technical problems, the first aspect of this invention provides a GLP-1 class drug microneedle delivery system, comprising: The microneedle carrier module includes multiple conductive microneedles arranged in an array; The glucose detection module is used to monitor the glucose concentration in subcutaneous tissue fluid in real time. Drug delivery module for loading and controlled release of GLP-1 drugs; The drug detection module is used to monitor the release concentration and cumulative release amount of GLP-1 drugs in real time; The glucose detection module, the drug loading module, and the drug detection module are each integrated onto a corresponding conductive microneedle; The closed-loop control system is connected to the glucose detection module, the drug delivery module, and the drug detection module respectively, and is used to receive glucose detection signals and drug detection signals, and control the drug release process of the drug delivery module according to the signals.

[0007] This invention achieves transdermal minimally invasive drug delivery and subcutaneous in-situ detection through a microneedle carrier module. A glucose detection module monitors the glucose concentration in subcutaneous tissue fluid in real time and provides a drug release trigger signal. A drug loading module loads and controls the release of GLP-1 drugs. A drug detection module monitors the release concentration and cumulative release amount of GLP-1 drugs in situ in real time and provides a drug concentration feedback signal. A closed-loop control system receives the glucose detection signal and the drug concentration detection signal and controls the drug release process of the drug loading module accordingly. This solves the technical problem of existing microneedle drug delivery systems being unable to monitor the release concentration of GLP-1 in situ and accurately control drug release in a closed loop. It achieves a closed-loop control process of "detection-release-monitoring-termination," effectively avoiding insufficient or excessive drug administration and significantly improving the accuracy and safety of drug delivery.

[0008] Furthermore, the glucose detection module includes glucose oxidase and peroxidase, which are modified on the surface of the conductive microneedle to form a dual-enzyme system. The glucose detection module employs a dual-enzyme system, exhibiting strong anti-interference capabilities and suitability for real-time monitoring in the complex physiological environment of subcutaneous tissue fluid. It utilizes the specificity of enzymatic reactions to achieve highly sensitive and selective detection of glucose concentration, providing an accurate and reliable drug release trigger signal for the closed-loop control system.

[0009] Furthermore, the drug delivery module includes a polypyrrole drug-loaded matrix and an electrically controlled release unit. The polypyrrole drug-loaded matrix is ​​disposed on the surface of the conductive microneedles for loading and immobilizing GLP-1 class drugs. The electrically controlled release unit is signal-connected to the closed-loop control system and is used to apply an electrical signal to the polypyrrole drug-loaded matrix to trigger or terminate drug release. The drug delivery module employs a combination of a polypyrrole drug-loaded matrix and an electrically controlled release unit. By triggering the oxidative expansion and reductive contraction of the polypyrrole chains through electrical signals, it achieves active and controllable release and precise termination of GLP-1 class drugs. Compared to passive chemical response drug release systems, the drug release behavior is not affected by fluctuations in the physiological environment and can be precisely started and stopped according to closed-loop control commands, meeting the precise control requirements for on-demand drug delivery.

[0010] Furthermore, the drug detection module includes a gold nanoparticle layer and a recognition element. The gold nanoparticle layer is disposed on the surface of the conductive microneedle, and the recognition element is fixed on the gold nanoparticle layer. The recognition element is a GLP-1 specific antibody. The drug detection module employs a combined structure of a gold nanoparticle layer and a GLP-1 specific antibody, achieving in-situ real-time detection of GLP-1 drug concentration based on the antigen-antibody specific recognition principle. The gold nanoparticle layer enhances the electrochemical signal transduction efficiency, and the antibody recognition element ensures high detection specificity, providing accurate feedback signals on drug release concentration and cumulative release amount for the closed-loop control system.

[0011] Furthermore, the microneedle carrier module also includes a base layer, and the conductive microneedles are integrally formed with the base layer. This integrally formed structure ensures the mechanical strength and structural stability of the microneedle array, guaranteeing that the microneedles can effectively pierce the stratum corneum of the skin without breaking, while also simplifying the fabrication process.

[0012] Furthermore, the conductive microneedles are 600-1000 μm in length, and the distance between the tips of adjacent conductive microneedles is 400-600 μm. This ensures that the microneedles penetrate to a depth sufficient to reach the subcutaneous tissue fluid without touching the pain nerves in the dermis, achieving minimally invasive and painless drug delivery. At the same time, the reasonable tip spacing ensures the effective distribution and independent operation of each functional module on the microneedle array.

[0013] Furthermore, the closed-loop control system includes: The signal processing unit is connected to the glucose detection module and the drug detection module respectively, and is used to receive and process the glucose detection signal and the drug concentration detection signal. The decision algorithm unit is connected to the signal processing unit and is used to generate drug release control commands based on the processed signals. An execution control unit is connected to the decision algorithm unit and the drug delivery module respectively, and is used to control the action of the drug delivery module according to the drug release control command to realize the initiation or termination of drug release.

[0014] The closed-loop control system achieves a complete control link from signal acquisition and data processing to drug release execution through the coordinated work of the signal processing unit, decision algorithm unit and execution control unit. The decision algorithm unit generates drug release control commands based on the dual signals of glucose concentration and drug release concentration, enabling the system to adaptively adjust the drug administration behavior according to the patient's real-time blood glucose level and drug release status, thereby improving the accuracy of individualized treatment.

[0015] Furthermore, the GLP-1 class drug microneedle delivery system also includes a flexible circuit board. The glucose detection module, the drug detection module, and the drug delivery module are electrically connected to the flexible circuit board, and the closed-loop control system is integrated on the flexible circuit board. By using a flexible circuit board to achieve electrical connection of each functional module and integration of the closed-loop control system, the system as a whole has flexible wearability, can conform to the curvature of the skin without affecting the microneedle puncture effect, and facilitates data interaction and remote monitoring with external terminals, improving patient convenience and treatment compliance.

[0016] A second aspect of the present invention provides a control method for the above-mentioned GLP-1 class drug microneedle delivery system, comprising the following steps: S1. The glucose detection module collects the glucose concentration in the subcutaneous tissue fluid in real time and transmits the glucose detection signal to the closed-loop control system. S2. The closed-loop control system determines whether the glucose concentration is higher than the preset threshold. When it is higher than the preset threshold, it sends a drug release command to the drug delivery module. S3. The drug delivery module responds to the drug release command and triggers the release of GLP-1 class drugs; S4. The drug detection module collects the release concentration and cumulative release amount of GLP-1 drugs in real time and feeds the drug detection signal back to the closed-loop control system. S5. The closed-loop control system determines whether the cumulative release amount has reached the preset therapeutic dose or whether the glucose concentration has fallen back to the safe threshold. When either condition is met, a termination command is sent to the drug delivery module. S6. The drug delivery module terminates drug release.

[0017] The control method of this invention achieves automated closed-loop control of GLP-1 drug administration through a complete process of glucose detection-triggered drug release, drug concentration feedback monitoring, and dual-condition termination of drug release. It can automatically adjust the drug administration process according to the real-time blood glucose level without the need for manual intervention by the patient, and automatically terminate the drug release when the preset therapeutic dose is reached or the blood glucose drops to a safe threshold, effectively avoiding the risks of drug overdose or underdose.

[0018] Further, in step S2, the preset threshold is 7-8 mM; in step S5, the safety threshold is 5-6 mM, and the preset therapeutic dose is 400-600 μg. By limiting the preset threshold, safety threshold, and preset therapeutic dose, the control method has clear clinical operating parameters. The preset threshold corresponds to the critical value of postprandial blood glucose elevation, which can trigger drug release in a timely manner; the safety threshold corresponds to the normal fasting blood glucose level, which can safely terminate drug release; and the preset therapeutic dose corresponds to the effective dose of a single treatment with GLP-1 drugs, ensuring accurate, safe, and effective drug administration.

[0019] In summary, compared with the prior art, the present invention has the following beneficial effects: (1) This invention constructs a dual closed-loop control system for the entire process of “blood glucose detection-drug release-release monitoring-drug release termination”. The glucose detection module provides a drug release trigger signal in real time, and the drug detection module monitors the release concentration and cumulative release amount of GLP-1 drugs in situ in real time and provides a drug concentration feedback signal. The closed-loop control system controls the drug release process of the drug delivery module together based on the glucose detection signal and the drug concentration detection signal. This solves the technical problem that existing microneedle drug delivery systems cannot monitor the release concentration of GLP-1 in situ and accurately control the drug release in a closed loop, effectively improving the accuracy and safety of drug release control.

[0020] (2) This invention combines a polypyrrole drug-loaded matrix with an electro-controlled release unit to achieve active electro-controlled release and precise termination of GLP-1 drugs. Compared with passive chemical response drug release systems, the drug release behavior is not affected by physiological environmental fluctuations and can be precisely started and stopped according to closed-loop control commands. At the same time, the drug detection module uses a gold nanoparticle layer and a GLP-1 specific antibody to achieve in-situ real-time detection based on the antigen-antibody specific recognition principle. The gold nanoparticle layer enhances the electrochemical signal transduction efficiency, and the antibody recognition element ensures high detection specificity, providing accurate and reliable feedback on drug release concentration and cumulative release amount for closed-loop control.

[0021] (3) The present invention adopts a microneedle array structure, the puncture depth is controllable, and it does not touch the pain nerves in the dermis, thus realizing minimally invasive and painless drug delivery; the system operates automatically, eliminating the need for frequent manual operation, significantly reducing the operational burden and the risk of local infection, and effectively improving user compliance, especially suitable for people with metabolic diseases who need long-term drug management.

[0022] (4) The present invention can adaptively adjust the release amount of GLP-1 drugs based on real-time blood glucose levels to achieve individualized and precise drug delivery. Through dual control of preset threshold and safety threshold, the system can start drug release in time when blood glucose rises and automatically terminate drug release when the preset release amount is reached or blood glucose falls back to the safe range, avoiding the risk of drug overdose or underdose; through precise release of GLP-1 drugs, it helps to achieve safe, efficient and sustainable weight management.

[0023] (5) This invention integrates glucose detection, drug loading, drug detection and closed-loop control into the same microneedle platform, and realizes the electrical connection and system integration of each functional module through a flexible circuit board. It has good flexible wearability and can fit the skin surface without affecting the microneedle puncture effect. At the same time, it is convenient to interact with external terminals for data and remote monitoring, improving the ease of use and intelligence level. It has broad application prospects in the field of intelligent medical care. Attached Figure Description

[0024] Figure 1 This is a schematic diagram of the structural framework of the GLP-1 class drug microneedle delivery system in a specific embodiment of the present invention.

[0025] Figure 2 This is a schematic diagram of the preparation process of the GLP-1 class drug microneedle delivery system in a specific embodiment of the present invention.

[0026] Figure 3 This is a scanning electron microscope image of the surface morphology of the microneedle array in an embodiment of the present invention.

[0027] Figure 4 The figure shows the mechanical performance test results of the microneedle array in an embodiment of the present invention.

[0028] Figure 5 This is a controlled release curve of GLP-1 class drugs in the drug delivery module in an embodiment of the present invention.

[0029] Figure 6 This is a sensitivity curve of the drug detection module for GLP-1 drugs in an embodiment of the present invention.

[0030] Figure 7 This is a graph showing the linear response of the glucose detection module to glucose detection in an embodiment of the present invention.

[0031] Figure 8 This is a diagram showing the biosafety assessment results of the GLP-1 class drug microneedle delivery system in an embodiment of the present invention.

[0032] Explanation of reference numerals in the attached figures: 100-Microneedle carrier module, 200-Glucose detection module, 300-Drug loading module, 400-Drug detection module, 500-Closed-loop control system, 501-Signal processing unit, 502-Decision algorithm unit, 503-Execution control unit, 600-Flexible circuit board. Detailed Implementation

[0033] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings.

[0034] It should be understood that the terminology used in this invention is merely for describing specific embodiments and is not intended to limit the invention. Furthermore, regarding numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0035] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be obvious to those skilled in the art. This application specification and embodiments are merely exemplary.

[0036] A specific embodiment of the present invention provides a GLP-1 class drug microneedle delivery system, combined with Figure 1 As shown, the system includes a microneedle carrier module 100, a glucose detection module 200, a drug loading module 300, a drug detection module 400, and a closed-loop control system 500. The glucose detection module 200, drug loading module 300, and drug detection module 400 are integrated into the microneedle carrier module 100. The closed-loop control system 500 is connected to the glucose detection module 200, drug loading module 300, and drug detection module 400 respectively, and is used to receive glucose detection signals and drug detection signals, and control the drug release process of the drug loading module 300 according to the signals.

[0037] Microneedle carrier module 100: includes a substrate layer and a microneedle array integrally formed with the substrate layer. The microneedle array consists of multiple conductive microneedles arranged in an array. In some specific embodiments, the length of a single conductive microneedle is 600~1000μm, and the tip spacing between adjacent conductive microneedles is 400~600μm. The conductive microneedles can be made of polystyrene microneedle substrate that has undergone surface conductive treatment, such as sputtering a platinum conductive layer on the surface of the microneedles.

[0038] Glucose detection module 200: Integrated onto a portion of the conductive microneedles, used for real-time monitoring of glucose concentration in subcutaneous tissue fluid. The glucose detection module 200 includes glucose oxidase and peroxidase, both modified onto the surface of the conductive microneedles to form a dual-enzyme system.

[0039] In some specific embodiments, Prussian blue nanoparticles are also deposited on the surface of the conductive microneedles as electron mediators, and glucose oxidase and peroxidase are immobilized on the microneedle surface via glutaraldehyde cross-linking. This module indirectly measures the glucose concentration by monitoring the amount of hydrogen peroxide generated by the enzymatic reaction.

[0040] Drug loading module 300: Integrated onto a portion of the conductive microneedles, used for loading and controlled release of GLP-1 class drugs. GLP-1 class drugs refer to glucagon-like peptide-1 receptor agonists, including but not limited to benaglutide, liraglutide, smegglutide, dulaglutide, exenatide, lixisenatide, etc., preferably benaglutide. All of the above-mentioned GLP-1 class drugs can be loaded and electrically controlled for release via the drug loading module 300, and can be detected in situ by the drug detection module 400.

[0041] In some specific embodiments, the drug-loading module 300 includes a polypyrrole drug-loading matrix and an electrically controlled release unit. The polypyrrole drug-loading matrix is ​​disposed on the surface of the conductive microneedles, and GLP-1 class drugs are embedded in the polypyrrole polymer network as an anionic dopant. The electrically controlled release unit is signal-connected to the closed-loop control system 500 and is used to apply an electrical signal to the polypyrrole drug-loading matrix to trigger or terminate drug release. When a weak positive voltage is applied, the polypyrrole chains undergo oxidative expansion, the interchain spacing increases, and the GLP-1 class drugs are released freely. When the electrical signal is removed or a weak reverse voltage is applied, the polypyrrole chains contract and compact, locking the drug and terminating the release.

[0042] Drug detection module 400: Integrated onto a portion of the conductive microneedles, used for real-time monitoring of the release concentration and cumulative release amount of GLP-1 drugs. Drug detection module 400 includes a gold nanoparticle layer and a recognition element. The gold nanoparticle layer is disposed on the surface of the conductive microneedles, and the recognition element is fixed on the gold nanoparticle layer. The recognition element is a GLP-1 specific antibody.

[0043] In some specific embodiments, gold nanoparticles are formed on the surface of a microneedle electrode via electrodeposition. GLP-1 specific antibodies are immobilized through the specific binding of the gold nanoparticles to the antibody's thiol groups, while non-specific active sites are blocked by a blocking agent. This module, based on the principle of antigen-antibody specific recognition, captures changes in electrochemical signals to achieve in-situ real-time detection of GLP-1 drug concentrations.

[0044] A closed-loop control system 500 receives glucose detection signals and drug detection signals, and controls the drug release process of the drug delivery module 300 based on these signals. The closed-loop control system 500 includes a signal processing unit 501, a decision algorithm unit 502, and an execution control unit 503. The signal processing unit 501 is connected to both the glucose detection module 200 and the drug detection module 400, and receives and processes the glucose detection signals and drug concentration detection signals. The decision algorithm unit 502 is connected to the signal processing unit 501 and generates drug release control commands based on the processed signals. The execution control unit 503 is connected to both the decision algorithm unit 502 and the drug delivery module 300, and controls the operation of the drug delivery module 300 according to the drug release control commands to initiate or terminate drug release.

[0045] In some specific embodiments, the decision algorithm unit 502 incorporates dual threshold control logic: drug release is initiated when the glucose concentration exceeds a preset threshold; drug release is terminated when the cumulative release amount of a single dosing cycle of the GLP-1 drug reaches a preset therapeutic dose or the glucose concentration drops to a safe threshold.

[0046] Flexible circuit board 600: Glucose detection module 200, drug detection module 400, and drug loading module 300 are electrically connected to flexible circuit board 600, and closed-loop control system 500 is integrated on flexible circuit board 600. Flexible circuit board 600 adapts to the flexible wearable requirements of microneedles conforming to the skin, and at the same time facilitates data interaction and remote monitoring with external smart terminals.

[0047] Combination Figure 2 As shown, the preparation method of the above-mentioned GLP-1 class drug microneedle delivery system includes the following steps: (1) Microneedle carrier preparation: A substrate layer with a microneedle array was prepared using a template centrifugation method. Specifically, polystyrene was dissolved in ethyl acetate and injected into a polydimethylsiloxane microneedle template. Centrifugation was performed to fill the template with the solution, and the substrate was dried and demolded to obtain a polystyrene microneedle substrate. The surface of the microneedles was then made conductive, for example, by depositing a platinum conductive layer on the surface of the microneedles using a vacuum sputtering method to obtain conductive microneedles.

[0048] (2) Construction of glucose detection module: A glucose response layer was constructed on the surface of some conductive microneedles. First, Prussian blue nanoparticles were deposited on the surface of the microneedles as electron mediators by electrodeposition. Then, glucose oxidase and peroxidase were immobilized on the surface of the microneedles by glutaraldehyde crosslinking. Specifically, the microneedles were immersed in PBS buffer containing glucose oxidase and peroxidase, glutaraldehyde was added for crosslinking, and after washing, the glucose detection module was obtained.

[0049] (3) Construction of drug-loaded module: A drug-loaded layer was constructed on the surface of some conductive microneedles. Electrochemical in-situ polymerization was used, with conductive microneedles as working electrodes. Polymerization was carried out in an electrolyte containing pyrrole monomers and GLP-1 drugs under constant potential, so that polypyrrole was generated in situ on the surface of the microneedles. GLP-1 drugs were used as anionic dopant to be incorporated into the polypyrrole polymer network. After polymerization, the surface of the microneedles was rinsed to remove unbound free drug and residual monomers, thus obtaining the drug-loaded module.

[0050] (4) Construction of drug detection module: A drug detection layer was constructed on the surface of some conductive microneedles. First, gold nanoparticles were deposited on the surface of the microneedles by electrodeposition. Then, the surface of the microneedles was sequentially hydroxylated and aminoized. Next, the GLP-1 specific antibody was fixed by glutaraldehyde crosslinking. Finally, the non-specific active sites were blocked with a blocking agent to obtain the drug detection module.

[0051] (5) Electronic control system integration: The electrodes of the glucose detection module, the electrodes of the drug detection module, and the electronically controlled release unit of the drug loading module are electrically connected to the flexible circuit board, and the closed-loop control system is integrated on the flexible circuit board to obtain the GLP-1 drug microneedle delivery system.

[0052] Specific embodiments also provide a control method for the above-mentioned GLP-1 class drug microneedle delivery system, including the following steps: S1. The glucose detection module collects the glucose concentration in the subcutaneous tissue fluid in real time and transmits the glucose detection signal to the closed-loop control system.

[0053] S2. The closed-loop control system determines whether the glucose concentration is higher than a preset threshold. If it is higher than the preset threshold, it sends a drug release control command to the drug delivery module. In some specific embodiments, the preset threshold is 7~8mM, preferably 7.8mM.

[0054] S3. The drug delivery module responds to the drug release control command and triggers the release of GLP-1 drugs. Specifically, the electronically controlled release unit of the drug delivery module applies an electrical signal to the polypyrrole drug delivery matrix, causing the polypyrrole chains to oxidize and expand, thus releasing the GLP-1 drugs.

[0055] S4. The drug detection module collects the release concentration and cumulative release amount of GLP-1 drugs in real time and feeds the sensor signals back to the closed-loop control system.

[0056] S5. The closed-loop control system determines whether the cumulative release amount has reached the preset therapeutic dose or whether the glucose concentration has fallen back to the safety threshold. When either condition is met, a termination control command is issued to the drug delivery module. In some specific embodiments, the safety threshold is 5~6mM, preferably 5.6mM; the preset therapeutic dose is 400~600μg, preferably 500μg.

[0057] S6. The drug delivery module terminates drug release. Specifically, the electronically controlled release unit cancels the electrical signal, causing the polypyrrole chains to contract and densify, thus terminating the release of GLP-1 class drugs.

[0058] The above control method achieves automated closed-loop control of the drug delivery process for GLP-1 drugs through a complete set of steps including glucose detection-triggered drug release, drug concentration feedback monitoring, and dual-condition termination of drug release. It can automatically adjust the drug release process based on real-time blood glucose levels without manual intervention, and automatically terminate drug release when the preset release amount is reached or blood glucose drops to a safe range, effectively improving the accuracy and safety of drug release control.

[0059] The technical effects of the present invention will be described below with reference to specific embodiments. Unless otherwise specified, the raw materials used in the embodiments of this application are all obtained through commercial means.

[0060] Example 1: Preparation of a GLP-1 class drug microneedle delivery system This embodiment prepares a GLP-1 class drug microneedle delivery system and characterizes its microneedle array morphology and mechanical properties, as follows: (1) Preparation of microneedle carrier module Using polystyrene (PS) as the material, 10g of polystyrene was weighed and added to a 100mL Erlenmeyer flask, along with 50mL of ethyl acetate. The mixture was stirred overnight at room temperature to dissolve, yielding a PS solution. 0.6mL of the PS solution was added to a polydimethylsiloxane (PDMS) microneedle template, and the template was centrifuged at 3000 rpm for 10 minutes. After the PS solution inside the template was completely dry, the template was demolded to obtain the PS microneedle substrate. The microneedle array used was a 4×4 conical array with a tip length of 600μm and a tip spacing of 600μm.

[0061] The PS microneedle was placed with its tip facing upward in the vacuum sputtering chamber. Metal deposition was performed using a platinum target as the metal source. The vacuum level of the deposition environment was 3.0 Pa, the deposition current was 30 mA, and the deposition time was 300 s, resulting in conductive microneedles.

[0062] (2) Construction of glucose detection module Prussian blue nanoparticles were deposited on the surface of some conductive microneedles as electron mediators using electrodeposition according to the predetermined arrangement. Then, the microneedles were immersed in PBS buffer (pH 7.4) containing glucose oxidase (10 mg / mL) and horseradish peroxidase (5 mg / mL), and 2.5% glutaraldehyde was added for crosslinking for 30 minutes. The microneedles were then washed three times with PBS buffer to obtain the glucose detection module.

[0063] (3) Construction of drug detection module Gold nanoparticles were deposited on the surface of some conductive microneedles using electrodeposition according to a predetermined arrangement. The microneedles were then immersed in an anhydrous ethanol solution of 150 mM 6-mercapto-1-hexanol for surface hydroxylation, followed by immersion in 95% ethanol solvent containing 10% APTES for 2 hours for surface amination. The microneedles were then immersed in a 2.5% glutaraldehyde solution for 2 hours, followed by antibody modification in a 500 μg / mL benaglutide antibody solution for 2 hours. Finally, they were blocked by immersion in a 100 mM ethanolamine solution and washed three times with deionized water to obtain the drug detection module.

[0064] (4) Construction of drug delivery module The drug-loaded module was constructed according to the predetermined arrangement. A polymerization-doped electrolyte was prepared in 0.1 mol / L PBS buffer (physiological pH 7.4). 0.2 mol / L pyrrole monomer and 0.05 mol / L sodium p-toluenesulfonate were added sequentially, and after thorough stirring, benaglutide active pharmaceutical ingredient was added to obtain a homogeneous polymerization electrolyte with a benaglutide concentration of 1.0 mg / mL. The electrolyte was stirred in the dark for 30 min. Using conductive microneedles as the working electrode, a platinum sheet as the counter electrode, and Ag / AgCl as the reference electrode, polymerization was carried out at a constant potential of 1.0 V for 500 s. This allowed the pyrrole monomer to oxidize and polymerize on the surface of the microneedle electrode to form a polypyrrole conductive film, while benaglutide was embedded as an anionic dopant into the polypyrrole network. After polymerization, the module was gently rinsed with PBS buffer and air-dried at room temperature in the dark to obtain the drug-loaded module.

[0065] (5) Electronic control system integration and system assembly The glucose detection electrode, drug detection electrode, and electrically controlled release unit are integrated into a single unit via flexible conductive circuitry and electrically connected to an external control circuit to assemble a GLP-1 class drug microneedle delivery system.

[0066] Example 2: Performance Testing of Microneedle Carrier Module This embodiment characterizes the morphology and mechanical properties of the microneedle carrier module prepared in Example 1.

[0067] Morphological characterization: The microneedle carrier module prepared in Example 1 was fixed to the scanning electron microscope sample holder using conductive tape, and the morphology of the microneedles was observed using field emission scanning electron microscopy (FE-SEM). The results are as follows: Figure 3 As shown. Figure 3 (a) shows the unmodified basic microneedle array, where the microneedles are arranged in a regular conical array, with an intact overall structure, a relatively smooth surface, sharp needle tips, and no obvious defects, meeting the physical requirements for skin puncture. Figure 3(b) shows the local morphology of the drug-loaded module microneedles. Compared with the basic microneedles, the surface of the microneedles is uniformly covered with a polypyrrole drug-loaded layer, exhibiting a distinctly rough granular morphology, indicating that benaglutide has been successfully loaded onto the surface of the microneedles, and the modified microneedles still maintain a complete conical shape and sharp tips. Figure 3 (c) shows the local morphology of the glucose detection module microneedles. An enzyme layer can be seen covering the surface of the microneedles. The morphology is slightly rougher than that of the basic microneedles, which confirms that biomolecules such as glucose oxidase have been successfully immobilized and a glucose detection interface has been constructed. At the same time, the microneedles still maintain a regular conical structure and a sharp tip.

[0068] Mechanical property testing: The microneedle carrier module was glued and fixed to the center of the base below the material mechanical property tester, with the needle tip facing upwards. The microneedle was compressed using the platform above the tester, and the change curve of force per needle as a function of displacement was recorded. The results are as follows: Figure 4 As shown, the force on the microneedle increases slowly in the initial pressure stage; as the displacement increases, the force rises rapidly and non-linearly; when the displacement reaches approximately 0.14 mm and the force on a single needle reaches approximately 1.21 N (indicated by the arrow in the figure), a clear inflection point appears on the curve, indicating that the microneedle has buckled or broken. The mechanical properties of the microneedle exhibit a fracture hardness of 1.21 N / needle in the pressure test, which is far greater than the 0.058 N / needle mechanical property requirement for skin puncture, indicating that the microneedle can effectively puncture the skin to achieve subcutaneous detection and drug delivery functions.

[0069] Example 3: Controlled release performance test of drug delivery module This embodiment evaluates the controlled release performance of benaglutide from the drug-loaded module prepared in Example 1.

[0070] The drug-loaded microneedle array was placed in PBS buffer (simulating a physiological environment) at 37℃ and pH 7.4. A three-electrode testing system was constructed using an Ag / AgCl electrode as the reference electrode and a platinum wire as the counter electrode. The release behavior of benaglutide was controlled by applying pulsed electrical signals through the electro-release unit of the closed-loop control system. The results are as follows: Figure 5 As shown: (1) Constant potential release: such as Figure 5 As shown in figure a, benaglutide was rapidly released when a +1.0V voltage was applied, with a cumulative release of 12μg within approximately 400s; after the voltage was removed, the release immediately ceased, and the release level remained at the baseline. In contrast, almost no drug release was detected in the 0V control group.

[0071] (2) Pulse-controlled release: such as Figure 5 As shown in b, by periodically applying / removing the electrical signal, benaglutide exhibits a stepwise increasing release pattern, with the release amount being positively correlated with the number of pulses, and the release behavior at each stage being stable.

[0072] The above results demonstrate that this drug delivery module, based on the electroresponsive properties of the polypyrrole conductive matrix, can achieve active electrocontrolled release and precise termination of benaglutide. Its drug release behavior is highly dependent on external electrical signals, unaffected by fluctuations in the physiological environment, and can achieve on-demand, quantitative programmed drug delivery according to closed-loop control commands.

[0073] Example 4: Performance Test of Drug Detection Module This embodiment evaluates the benaglutide detection performance of the drug detection module prepared in Example 1.

[0074] A three-electrode system was constructed using a microneedle from the drug detection module as the working electrode, an Ag / AgCl electrode as the reference electrode, and a platinum wire electrode as the counter electrode. The microneedles were immersed in benaglutide solutions of different concentrations (0, 10, 50, 100, 150, 200 ng / mL) for amperometric detection. Results are as follows: Figure 6 As shown: (1) Time-current response: such as Figure 6 As shown in Figure a, after applying a constant potential, each concentration group rapidly generates a reduction current and tends to stabilize; the absolute value of the current response increases significantly with increasing benaglutide concentration.

[0075] (2) Linear response relationship: such as Figure 6 As shown in b, the absolute value of steady-state current showed a good negative linear correlation with the concentration of benaglutide in the range of 0~200 ng / mL, and the linear regression equation was y=-0.00474x+1.812 (where y is the current in μA; x is the concentration of benaglutide in ng / mL).

[0076] The results show that the drug detection module can achieve high specificity and high sensitivity in situ detection of benaglutide, and can provide accurate feedback signals of benaglutide release concentration and cumulative release amount for the closed-loop control system, thereby guiding the electro-controlled drug release behavior of the drug delivery module.

[0077] Example 5: Performance Test of Glucose Detection Module This embodiment evaluates the glucose detection performance of the glucose detection module prepared in Example 1.

[0078] A three-electrode system was constructed using a glucose detection module microneedle as the working electrode, an Ag / AgCl electrode as the reference electrode, and a platinum wire electrode as the counter electrode for amperometric detection. The microneedle was placed in PBS buffer, and glucose was added sequentially to final concentrations of 10, 20, 40, and 50 mM. Results are as follows: Figure 7 As shown: (1) Time-current response: such as Figure 7As shown in Figure a, the current stabilizes at approximately 9.8 μA at the PBS baseline state; as the glucose concentration gradually increases, the current exhibits a clear stepwise increase, reaching approximately 15.5 μA at 50 mM, indicating that the module has a rapid and reversible response to glucose.

[0079] (2) Linear response relationship: such as Figure 7 As shown in b, the steady-state current value and glucose concentration exhibit a good positive linear correlation in the range of 10~50mM, and the correlation coefficient R of the linear regression equation is [value missing]. 2 =0.9551.

[0080] The results show that the glucose detection module has a wide linear detection range and good sensitivity, which can meet the needs of real-time monitoring of glucose concentration in subcutaneous tissue fluid and provide reliable data support for the decision-making of closed-loop control systems.

[0081] Example 6: Biosafety Assessment This embodiment evaluates the biosafety of the GLP-1 class drug microneedle delivery system prepared in Example 1.

[0082] After sterilization, the microneedle delivery system was placed in a sterile culture dish and immersed in high-glucose DMEM medium containing 10% fetal bovine serum. Mouse epithelial-like fibroblast L929 cells were seeded at a density of 20,000 cells / well in 96-well cell culture plates and cultured for 24 h. The original medium was discarded, and the above microneedle extract was added for further culture for 24 h (an untreated group was set up as a control group Ctrl). After 24 h of culture, live and dead cells were stained with Calcein-AM / PI, and cell viability was observed using a fluorescence microscope.

[0083] The results are as follows Figure 8 As shown in the image, from left to right, the images represent live cell staining, dead cell staining, and a merged image. Quantitative image analysis revealed that the cell viability of the microneedle treatment group (MN) was greater than 95%, with no significant difference compared to the control group (Ctrl).

[0084] The above results demonstrate that the microneedle drug delivery system has good biocompatibility, no obvious cytotoxicity, and meets the biosafety requirements for subcutaneous implantation / puncture drug delivery, providing a safety guarantee for the clinical application of closed-loop control systems.

[0085] Example 7: Verification of Control Method for Closed-Loop Control System This embodiment verifies the closed-loop control method of the GLP-1 class drug microneedle delivery system prepared in Example 1.

[0086] The closed-loop control system uses an STM32F407 microprocessor as its core control module. It receives glucose and drug detection signals and uses a built-in decision algorithm to determine whether to initiate or terminate drug release. The decision algorithm is based on dual threshold control: drug release is initiated when the glucose concentration exceeds 7.8 mM; drug release is terminated when the cumulative release of benaglutide in a single dosing cycle reaches the preset therapeutic dose of 500 μg or the glucose concentration drops to 5.6 mM.

[0087] The control method includes the following steps: a glucose detection module collects the glucose concentration in subcutaneous tissue fluid in real time and transmits the glucose detection signal to a closed-loop control system; the closed-loop control system determines whether the glucose concentration is higher than 7.8 mM, and when it is higher than 7.8 mM, it sends a drug release control command to the drug delivery module; the electro-controlled release unit of the drug delivery module applies an electrical signal to the polypyrrole drug delivery matrix to trigger the release of benaglutide; the drug detection module collects the release concentration and cumulative release amount of benaglutide in real time and feeds the sensor signal back to the closed-loop control system; the closed-loop control system determines whether the cumulative release amount reaches 500 μg or whether the glucose concentration drops back to 5.6 mM, and when either condition is met, it sends a termination control command to the drug delivery module; the electro-controlled release unit cancels the electrical signal, the polypyrrole chains contract and densify, and the release of benaglutide is terminated.

[0088] The verification results show that the closed-loop control system can automatically adjust the drug release process according to the real-time blood glucose level and drug release concentration, realize the closed-loop control of the entire process of "detection-release-monitoring-termination", and complete the precise drug release and automatic termination without manual intervention, effectively improving the accuracy and safety of drug release control.

[0089] While the present invention has been disclosed above, its scope of protection is not limited thereto. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of this disclosure, and all such changes and modifications will fall within the scope of protection of this invention.

Claims

1. A GLP-1 class drug microneedle delivery system, characterized in that, include: The microneedle carrier module includes multiple conductive microneedles arranged in an array; The glucose detection module is used to monitor the glucose concentration in subcutaneous tissue fluid in real time. Drug delivery module for loading and controlled release of GLP-1 drugs; The drug detection module is used to monitor the release concentration and cumulative release amount of GLP-1 drugs in real time; The glucose detection module, the drug loading module, and the drug detection module are each integrated onto a corresponding conductive microneedle; The closed-loop control system is connected to the glucose detection module, the drug delivery module, and the drug detection module respectively, and is used to receive glucose detection signals and drug detection signals, and control the drug release process of the drug delivery module according to the signals.

2. The GLP-1 class drug microneedle delivery system according to claim 1, characterized in that, The glucose detection module includes glucose oxidase and peroxidase, which are modified on the surface of the conductive microneedles to form a dual-enzyme system.

3. The GLP-1 class drug microneedle delivery system according to claim 1, characterized in that, The drug delivery module includes a polypyrrole drug delivery matrix and an electrically controlled release unit. The polypyrrole drug delivery matrix is ​​disposed on the surface of the conductive microneedles for loading and immobilizing GLP-1 drugs. The electrically controlled release unit is signal-connected to the closed-loop control system and is used to apply an electrical signal to the polypyrrole drug delivery matrix to trigger or terminate drug release.

4. The GLP-1 class drug microneedle delivery system according to claim 1, characterized in that, The drug detection module includes a gold nanoparticle layer and a recognition element. The gold nanoparticle layer is disposed on the surface of the conductive microneedle, and the recognition element is fixed on the gold nanoparticle layer. The recognition element is a GLP-1 specific antibody.

5. The GLP-1 class drug microneedle delivery system according to claim 1, characterized in that, The microneedle carrier module also includes a base layer, and the conductive microneedles are integrally formed with the base layer.

6. The GLP-1 class drug microneedle delivery system according to claim 5, characterized in that, The conductive microneedles have a length of 600~1000μm and a tip spacing of 400~600μm between adjacent conductive microneedles.

7. The GLP-1 class drug microneedle delivery system according to claim 1, characterized in that, The closed-loop control system includes: The signal processing unit is connected to the glucose detection module and the drug detection module respectively, and is used to receive and process the glucose detection signal and the drug concentration detection signal. The decision algorithm unit is connected to the signal processing unit and is used to generate drug release control commands based on the processed signals. An execution control unit is connected to the decision algorithm unit and the drug delivery module respectively, and is used to control the action of the drug delivery module according to the drug release control command to realize the initiation or termination of drug release.

8. The GLP-1 class drug microneedle delivery system according to any one of claims 1-7, characterized in that, It also includes a flexible circuit board, the glucose detection module, the drug detection module and the drug loading module are electrically connected to the flexible circuit board respectively, and the closed-loop control system is integrated on the flexible circuit board.

9. A control method for a GLP-1 class drug microneedle delivery system as described in any one of claims 1-8, characterized in that, Includes the following steps: S1. The glucose detection module collects the glucose concentration in the subcutaneous tissue fluid in real time and transmits the glucose detection signal to the closed-loop control system. S2. The closed-loop control system determines whether the glucose concentration is higher than the preset threshold. When it is higher than the preset threshold, it sends a drug release command to the drug delivery module. S3. The drug delivery module responds to the drug release command and triggers the release of GLP-1 class drugs; S4. The drug detection module collects the release concentration and cumulative release amount of GLP-1 drugs in real time and feeds the drug detection signal back to the closed-loop control system. S5. The closed-loop control system determines whether the cumulative release amount has reached the preset therapeutic dose or whether the glucose concentration has fallen back to the safe threshold. When either condition is met, a termination command is sent to the drug delivery module. S6. The drug delivery module terminates drug release.

10. The control method according to claim 9, characterized in that, In step S2, the preset threshold is 7~8mM; in step S5, the safety threshold is 5~6mM, and the preset treatment dose is 400~600μg.

Citation Information

Patent Citations

  • PEBA-based intelligent insulin microneedle patch and preparation method thereof

    CN120860452A

  • Microneedle sensor, application thereof and intelligent microneedle closed-loop system

    CN122250998A